Predictive Oncology (Predictive Oncology) Institutional Ownership : 5.08% (As of Apr. 29, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Predictive Oncology's institutional ownership is 5.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Predictive Oncology's Insider Ownership is 8.76%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Predictive Oncology's Float Percentage Of Total Shares Outstanding is 97.02%.

Predictive Oncology Institutional Ownership Historical Data

The historical data trend for Predictive Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Institutional Ownership Chart

Predictive Oncology Historical Data

The historical data trend for Predictive Oncology can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	8.34	8.34	6.56	6.66	4.96	4.98	4.97	5.12	5.08	5.08

Predictive Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Predictive Oncology (Predictive Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Executives

Robert L Myers	officer: CHIEF FINANCIAL OFFICER	4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr	director	633 1ST STREET WEST, SONOMA CA 95476
Veena Rao	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr	director	1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch	director	P O BOX 1572, PEPPERELL MA 01463
Pamela Bush	officer: Chief Business Officer	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley	director	1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith	director	151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle	director	1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz	10 percent owner	20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel	director	900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121